Navigation Links
Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission

WESTMINSTER, Colo., April 19, 2007 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. today announced that the Commission of the European Communities, with a favorable opinion of the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA), has granted orphan drug designation to the Company's novel antifolate PDX (pralatrexate) for the treatment of patients with peripheral T-cell lymphoma (PTCL). In July 2006, the U.S. Food and Drug Administration (FDA) awarded orphan drug designation to PDX for the treatment of patients with T-cell lymphoma. In October 2006, the FDA granted fast track designation to PDX for the treatment of patients with T-cell lymphoma.

"This designation underscores the critical need for new therapies to treat peripheral T-cell lymphoma and reinforces our belief that PDX has the potential to become an important therapeutic option for patients with this devastating disease," said Paul L. Berns, President and Chief Executive Officer.

The EMEA Orphan Medicinal Product Designation is intended to promote the development of drugs that may provide significant benefit to patients suffering from rare diseases identified as life-threatening or very serious. Under EMEA guidelines, Orphan Medicinal Product Designation provides ten years of potential market exclusivity once the product candidate is approved for marketing for the designated indication in the European Union. Orphan Medicinal Product Designation also provides potential protocol assistance, advice on the conduct of clinical trials, a reduced Marketing Authorization Application (MAA) filing fee for the drug's sponsor and the potential for grant funding.

PDX is currently the subject of PROPEL, a pivotal Phase 2, international, multi-center, open-label, single-arm study that will seek to enroll 100 evaluable patients with relapsed or refractory PTCL who have progressed after at least one prior treatmen
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
5. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
6. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
7. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
10. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:10/7/2008)...enu Expanded to Eight On-Demand Tests for Use on t...stem, SUNNYVALE, Calif., Oct. 7 /PRNewswire-First...e release of Xpert(TM) vanA/vanB as a European CE,...n Vitro Diagnostic,Medical Devices. The test deliv... genes most commonly associated with vancomycin-re...
(Date:10/6/2008)... and CHIPPENHAM, England, October 7 /PRNewswire-Fi...Mothers Index: 4565) and Vectura,Group plc ("Vectu...tudies,evaluating the efficacy, safety and tolerab...f the European Respiratory Society (ERS) in Berlin...ronium bromide), a novel,inhaled long-acting musca...
(Date:10/6/2008)... Data Presented at the American College of Gastroe...eting, ORLANDO, Fla., Oct. 6 /- Comb... the American College of Gastroenterology Annual,S...ated that TAK-390MR,resulted in higher healing rat...re grades of erosive esophagitis (EE). TAK-390MR c...
(Date:10/6/2008)... technology opens the door to the understanding of...betes, ageing and cancer, BILLERICA, Mass., Oct. ...ced the release of the first ever analytical instr... oxygen consumption and cytoplasmic,glycolysis in ...rs tools,for measuring cellular bioenergetics have...
Breaking Medicine Technology:Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 3Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 2Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 3Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 2Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 3Research cautions to catch and release in less than 4 minutes 597 1Research cautions to catch and release in less than 4 minutes 597 2Wyeth Announces the Election of Robert M Amen to Its Board of Directors 2260 1Statement of DePuy Orthopaedics Inc Regarding Agreement with U S Attorneys Office 2258 1Statement of DePuy Orthopaedics Inc Regarding Agreement with U S Attorneys Office 2258 2Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 2256 1Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 2256 2Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 2256 3Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 2256 4Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 2256 5
...XT-ALIGN: left; tab-stops: 0in",align="left"> , ,<...in; mso-list: l1 level1 lfo2">, <span style=,"FONT...di-font-weight: bold">,Independent Japanese study ... conventional therapy , , , ,<li style=,"MARGIN...level1 lfo2">, <span style=,"FONT-SIZE: 11pt; FONT...
...007 –,Merck Serono S.A. (virt-x: SEO) and it...) announced today that Professor,Fabrizio Stocchi,...ase III trial of safinamide as an adjunctive treat...rsquo;s disease (PD),patients at the American Acad... Boston from 28 April to 5 May 2007. , The abstrac...
Other Medicine Technology:Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 8Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 9Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 10Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 11Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 12Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 2Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 3Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 4
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...the US are at an advanced stage but it could be a ...ays an expert involved in the project. // "You mu...e large numbers of people involved and we have to ...ds. We are on the way but it will be a while befor...
... by extreme and irrational fear of simple things o...ctly what causes this. // To overcome this scient...l in the trial stage. The remedy developed by a S...ns a human hormone called cortisol, which the body...
... testicular cells obtained from male mice into emb...at have the remarkable ability to transform into o...the same could be achieved in humans, helping sett...ith the derivation of embryonic stem cells from un...
...on, Iowa, is currently witness to the combined res...on with the money // and Technological prowess of...n the ubiquitous sorghum crop that is the only suc... The joint venture, targeting sorghum, a widely kn...
Other Medicine News:Health News:HIV Vaccine Field Trials In Advanced Stage 2
...eica ASP200 is an advanced smart processor for par...ne histopathology applications. Proven and enhance... smart operating software are the hallmark of the ...ed and the software includes a variety of SMART fe...
The electronic, motorized rotary microtomes are designed for all applications of paraffin, semi-thin (HM 360), and hard specimens in clinical, research, and industrial labs. These instruments display
...eica RM2255 rotary microtome, designed for fully m...bedded specimens, offers a broad application spect...ory. This microtome meets the requirements of user...c microtome for their laboratory. The entire acces...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user.
Medicine Products: